Prior exposure to advanced therapy and timing of discontinuation and risk of serious infections in patients with inflammatory bowel disease initiating a new advanced therapy

Virginia Solitano

doi:10.1093/ecco-jcc/jjag095

Prior exposure to advanced therapy and timing of discontinuation and risk of serious infections in patients with inflammatory bowel disease initiating a new advanced therapy

2026-06-30

0

PRE

AI

V

Virginia Solitano

D

Dhruv Ahuja

Y

Yuchen Qi

S

Sagar B Patel

M

Marianne Hupé

S

Sudheer K Vuyyuru

A

Anna L Silverman

R

Ronghui Xu

S

Shane W Goodwin

O

Ola Olén

A

Ashwin N Ananthakrishnan

V

Vipul Jairath

S

Siddharth Singh *

DOI：10.1093/ecco-jcc/jjag095

Original

Original request for help

Save

Abstract

En 中文

Despite regulatory mandates for advanced therapy (AT) washout periods of up to 5 drug half-lives before enrolling patients in inflammatory bowel disease (IBD) trials, the evidence base for these requirements is largely empirical, and whether shorter intervals independently increase the risk of serious infections in real-world practice remains unknown.

Prior exposure to advanced therapy and timing of discontinuation and risk of serious infections in patients with inflammatory bowel disease initiating a new advanced therapy

Abstract

Journal

Organization